# RCT of Efficacy and Safety of CP003 on CFS/ME or Post-COVID Fatigue

> **NCT06739720** · PHASE2,PHASE3 · NOT_YET_RECRUITING · sponsor: **The University of Hong Kong** · enrollment: 130 (estimated)

## Conditions studied

- Chronic Fatigue Syndrome (CFS)
- Post-COVID ME/CFS

## Interventions

- **DRUG:** LingZhi capsule

## Key facts

- **NCT ID:** NCT06739720
- **Lead sponsor:** The University of Hong Kong
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-01-02
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-12-31
- **Target enrollment:** 130 (ESTIMATED)
- **Last updated:** 2024-12-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06739720

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06739720, "RCT of Efficacy and Safety of CP003 on CFS/ME or Post-COVID Fatigue". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06739720. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*